Quantity of qualified clients: CDEC talked over the uncertainty in the quantity of patients with reasonably intense to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some clients who are categorised as acquiring delicate or moderate condition may have a serious bleeding phen